Login to Your Account

Nightstar shines light down IPO well, seeks $86.2M for CHM phase III

By Randy Osborne
Staff Writer

Friday, September 1, 2017

Nightstar Therapeutics Ltd. filed to raise about $86.2 million in an IPO to advance its gene therapy candidate, NSR-REP1, for choroideremia (CHM), due to enter phase III trials in the first half of next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription